A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy
Tekijät: Pettilä V, Kaaja R, Leinonen P, Ekblad U, Kataja M, Ikkala E
Julkaisuvuosi: 1999
Journal: Thrombosis Research
Tietokannassa oleva lehden nimi: Thrombosis research
Lehden akronyymi: Thromb Res
Vuosikerta: 96
Numero: 4
Aloitussivu: 275
Lopetussivu: 82
Sivujen määrä: 8
ISSN: 0049-3848
DOI: https://doi.org/10.1016/S0049-3848(99)00110-3
Tiivistelmä
Venous thromboembolism remains an important cause of maternal mortality. For women at risk during pregnancy, the recommended venous thromboembolismprophylaxis is unfractionated heparin. Low molecular weight heparins, such as dalteparin, also may be suitable, but randomised trials have not been performed. Pregnant women (105) with confirmed previous or current thromboembolism were randomised to receive either unfractionated heparin twice daily (mean 20569 IU/day) or dalteparin once daily (mean 4631 IU anti-factor Xa units/day) subcutaneously for thromboprophylaxis during pregnancy and postpartum period. Recurrence of venous thromboembolism and safety of treatments were assessed. Dalteparin administered once daily was safe and effective in thromboprophylaxis during pregnancy and postpartum.
Venous thromboembolism remains an important cause of maternal mortality. For women at risk during pregnancy, the recommended venous thromboembolismprophylaxis is unfractionated heparin. Low molecular weight heparins, such as dalteparin, also may be suitable, but randomised trials have not been performed. Pregnant women (105) with confirmed previous or current thromboembolism were randomised to receive either unfractionated heparin twice daily (mean 20569 IU/day) or dalteparin once daily (mean 4631 IU anti-factor Xa units/day) subcutaneously for thromboprophylaxis during pregnancy and postpartum period. Recurrence of venous thromboembolism and safety of treatments were assessed. Dalteparin administered once daily was safe and effective in thromboprophylaxis during pregnancy and postpartum.
Turun yliopiston Tutkimustietojärjestelmän portaali